Identification of biomarkers for COVID-19 associated secondary hemophagocytic lymphohistiocytosis.

ABSTRACT:

Objectives

We aimed to define and validate novel biomarkers that could identify individuals with COVID-19 associated secondary hemophagocytic lymphohistiocytosis (sHLH) and to test whether fatalities due to COVID-19 in the presence of sHLH were associated with specific defects in the immune system.

Design

In two cohorts of adult patients presenting with COVID-19 in 2020 and 2021, clinical lab values and serum proteomics were assessed. Subjects identified as having sHLH were compared to those with COVID-19 without sHLH. Eight deceased patients defined as COVID-sHLH underwent genomic sequencing in order to identify variants in immune-related genes.

Setting

Two tertiary care hospitals in Seattle, Washington (Virginia Mason Medical Center and Harborview Medical Center).

SUBMITTER: Canny SP 

PROVIDER: S-EPMC11343163 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature